Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Safirstein Metcalf LLP Announces that a Class Action Has Been Filed Against Akers Biosciences, Inc. – AKER

TNFA, ORA

NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a class action has been filed on behalf of those who purchased securities of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ:AKER) between May 15, 2017 and June 5, 2018, both dates inclusive (the "Class Period").

If you purchased Akers Biosciences securities during the Class Period and would like more information about the shareholder class action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email info@SafirsteinMetcalf.com

If you wish to serve as lead plaintiff, you must move the Court no later than August 13, 2018.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, Defendants' statements about Akers' business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

About Safirstein Metcalf LLP

Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection.  All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Safirstein Metcalf LLP
Peter Safirstein, Esq.
The Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
1-800-221-0015

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today